GALT
Galectin Therapeutics Inc.
Set alert
- YTD
- -20.19%
- 1 year
- -34.52%
- Open
- 3.52
- Prev close
- 3.52
- Mkt cap
- 334.82M
- Vol
- 174.75K
- Avg vol
- 294.60K
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.27
- High
- 3.54
- Forward P/E
- -0.53
- Beta
- 0.63
- Short ratio
- 42.37
- Inst. own
- 15.77%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.51
- 200-d avg
- 2.64
- 1y target
- 11.00
Key statistics
- Market cap
- 55.86M
- Enterprise value
- 241.35M
- Trailing P/E
- 0.00
- Forward P/E
- -0.53
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.73
- Beta
- 0.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.36M
- Total cash
- 25.60M
- Total debt
- 93.47M
- Return on equity
- 0.00%
- Shares outstanding
- 62.76M
- Short % of float
- 18.41%
- 50-day average
- 2.51
- 200-day average
- 2.64
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.18 | +0.02 | +10.00% |
| Aug 13, 2024 | Jun 1, 2024 | -0.16 | -0.20 | -0.04 | -25.00% |
| May 15, 2024 | Mar 1, 2024 | -0.16 | -0.19 | -0.03 | -18.75% |
| Mar 29, 2024 | Dec 1, 2023 | -0.16 | -0.16 | 0.00 | 0.00% |
| Nov 13, 2023 | Sep 1, 2023 | -0.16 | -0.24 | -0.08 | -50.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.21 | -0.15 | +0.06 | +28.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- galectintherapeutics.com
News
- Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ)
- 20 stocks likely to lose money even if the bull market continues
- Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average – Here’s What Happened
- Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
- Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Galectin Therapeutics Converts ~$105.8M Of Debt Into ~34.4M Shares At Blended Average Conversion Price Of ~$3.07 Per Share
Your note
Sign in to keep a note on GALT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CZIRR JAMES C | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 22, 2024 | 0 |
| ELDRED KARY N. | Director | Purchase | Oct 22, 2024 | 54,638 |
| FREEMAN KEVIN D | Director | Purchase | Oct 16, 2024 | 132,832 |
| LEWIS JOEL | Chief Executive Officer | Purchase | Apr 23, 2024 | 0 |
| UIHLEIN RICHARD E | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jan 23, 2024 | 10,296,500 |
| ZORDANI RICHARD A. JR | Director | Purchase | Aug 22, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.40% | 2,134,205 | 1.90M | Sep 29, 2024 |
| Blackrock Inc. | 2.56% | 1,607,124 | 1.43M | Sep 29, 2024 |
| Osaic Holdings Inc | 1.88% | 1,182,095 | 1.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.37% | 862,542 | 767.75K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.77% | 483,264 | 430.15K | Sep 29, 2024 |
| Wealthspire Advisors, LLC | 0.63% | 398,374 | 354.59K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.99% | 1,247,562 | 1.11M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.07% | 670,160 | 596.51K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.59% | 372,101 | 331.21K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 278,527 | 247.92K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.32% | 198,844 | 176.99K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.17% | 107,352 | 95.55K | Oct 30, 2024 |